TG Therapeutics
Filed with the SEC on · accession 0001628280-26-072257
TGTX filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. TG Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including product revenue and license revenue. The stock moved +5.9% by the first close after the filing.
TG Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including product revenue and license revenue. The filing contains standard quarterly financial statements and disclosures.
Close before
$59.83
Nov 6, 2026
First close after
+5.94%
$63.38
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for TGTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for TGTX?
Click hereTGTX filed a 10-Q (SEC filing). TG Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including product revenue and license revenue. The filing contains standard quarterly financial statements and disclosures.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
TGTX closed at $59.83 before the filing and $63.38 on Nov 9, 2026 (+5.94%).
Get alerts when TGTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days